Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

About the company

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

77

CEO

Neal S. Walker

Exchange

NASDAQ

Website

http://www.aclaristx.com

$4.00M

Total Revenue

77

Employees

$81.18M

Market Capitalization

-0.59

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$0M

Operating Margin (in %)

Total operating margin

$M

Net Margin (in %)

Total net margin

$M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 12018.30 1376.00 5.12 18.95 43.06
Catalent, Inc. CTLT 11623.49 2872.00 5.84 111.44 3.63
Perrigo Co. Plc PRGO 7558.29 4837.00 1.30 51.56 3.02
Jazz Pharmaceuticals Plc JAZZ 6076.20 2188.00 2.10 22.21 12.81
Bausch Health Cos., Inc. BHC 6068.07 8597.00 8.47 -3.21 -21.96
United Therapeutics Corp. UTHR 5049.92 1443.00 1.75 9.75 36.59
MyoKardia, Inc. MYOK 4271.56 34.00 12.41 -13.78 -201.73
Axsome Therapeutics, Inc. AXSM 2906.40 None 19.72 -32.31 None
Pacira Biosciences, Inc. PCRX 2427.60 435.00 6.51 -5780.00 -0.02
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
SAGE Therapeutics, Inc. SAGE 2231.84 9.00 2.62 -3.45 -413.06
Corcept Therapeutics, Inc. CORT 2013.00 335.00 4.62 18.97 31.64
Prestige Consumer Healthcare, Inc. PBH 1863.54 963.00 1.57 13.14 14.77
Revolution Medicines, Inc. RVMD 1798.91 48.00 4.67 -25.41 -146.29
Madrigal Pharmaceuticals, Inc. MDGL 1558.65 0.00 4.16 -15.26 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1548.02 440.00 -21.91 18.26 19.14
Innoviva, Inc. INVA 1520.98 285.00 3.60 7.87 66.41
Intercept Pharmaceuticals, Inc. ICPT 1442.88 272.00 -42.94 -4.21 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Supernus Pharmaceuticals, Inc. SUPN 1309.50 402.00 2.08 11.23 28.90
Theravance Biopharma, Inc. TBPH 1232.34 88.00 -8.65 -4.99 -280.80
Zogenix, Inc. ZGNX 1225.80 5.00 3.35 -2.88 -241.62
Revance Therapeutics, Inc. RVNC 1161.84 0.00 4.59 -6.23 41.82
Amphastar Pharmaceuticals, Inc. AMPH 996.66 327.00 2.49 19.56 15.90
Endo International Plc ENDP 784.32 3014.00 -1.07 -2.80 -9.09
BellRing Brands, Inc. BRBR 762.45 954.00 -0.41 5.78 13.98
Eagle Pharmaceuticals, Inc. EGRX 678.30 192.00 3.65 269.17 1.29
Assembly Biosciences, Inc. ASMB 667.58 16.00 2.99 -6.71 -601.75
Aerie Pharmaceuticals, Inc. AERI 613.18 79.00 4.86 -3.03 -252.92
Collegium Pharmaceutical, Inc. COLL 582.76 299.00 4.17 -45.11 -4.21
Intersect ENT, Inc. XENT 577.76 102.00 5.45 -11.57 -48.61
Catalyst Pharmaceuticals, Inc. CPRX 528.58 119.00 5.15 12.05 36.09
Anika Therapeutics, Inc. ANIK 494.90 125.00 1.71 17.85 22.73
BioDelivery Sciences International, Inc. BDSI 388.24 130.00 5.55 -52.75 -5.01
Albireo Pharma, Inc. ALBO 326.82 11.00 3.32 -4.28 -730.55
ANI Pharmaceuticals, Inc. ANIP 326.76 203.00 1.67 -209.46 -0.67
MEI Pharma, Inc. MEIP 275.56 5.00 4.74 -7.06 -539.48
Mallinckrodt Plc MNK 199.08 3037.00 0.11 -0.17 -39.56
Agile Therapeutics, Inc. AGRX 147.85 None 2.41 -7.16 None
Marinus Pharmaceuticals, Inc. MRNS 146.79 0.00 5.68 -2.18 None
Cerecor, Inc. CERC 118.22 7.00 7.56 -5.24 -429.22
Ampio Pharmaceuticals, Inc. AMPE 98.67 1.00 69.00 -5.31 None
Zynerba Pharmaceuticals, Inc. ZYNE 85.79 0.00 1.41 -2.39 -699.94
AcelRx Pharmaceuticals, Inc. ACRX 84.80 2.00 -1.56 -1.51 -644.25
Evoke Pharma, Inc. EVOK 83.28 None 28.92 -12.39 None
Aclaris Therapeutics, Inc. ACRS 81.18 4.00 1.42 -0.59 None
Adamas Pharmaceuticals, Inc. ADMS 75.32 57.00 -4.80 -0.81 -160.44
CTI BioPharma Corp. CTIC 71.98 3.00 3.21 -1.74 -111.83
Cassava Sciences, Inc. SAVA 63.46 41.00 3.34 -13.92 76.71
Oramed Pharmaceuticals, Inc. ORMP 59.94 3.00 4.83 -4.69 -464.15
SCYNEXIS, Inc. SCYX 48.28 0.00 10.14 -1.25 -30.84
Cumberland Pharmaceuticals, Inc. CPIX 47.70 47.00 0.97 -10.60 -9.59
Natural Alternatives International, Inc. NAII 47.67 114.00 0.65 -12.61 -3.19
IsoRay, Inc. ISR 44.22 9.00 8.25 -13.20 -36.08
Lipocine, Inc. LPCN 40.20 0.00 9.57 -2.68 None
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 34.50 65.00 -2.65 -1.97 -26.74
PLx Pharma, Inc. PLXP 25.56 0.00 -2.45 -2.70 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 19.92 3.00 2.48 -1.68 -264.21
Regulus Therapeutics, Inc. RGLS 17.22 0.00 1.52 -0.80 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.15 8.00 0.64 -0.14 -798.18
Intec Pharma Ltd. NTEC 10.18 None 1.31 -0.24 None
Hepion Pharmaceuticals, Inc. HEPA 7.50 None 2.34 -0.63 None
Sonoma Pharmaceuticals, Inc. SNOA 6.44 19.00 1.02 -2.06 -25.58
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
VIVUS, Inc. VVUS 5.83 73.00 -0.13 -0.20 -39.28
Tonix Pharmaceuticals Holding Corp. TNXP 4.48 None 1.12 -0.09 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Is Aclaris Therapeutics, Inc. (ACRS) A Good Stock To Buy?

16d ago, source: YAHOO!

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will ...

Aclaris Therapeutics Inc.

6d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Aclaris Therapeutics Takes the Next Big Step Toward COVID Treatment

25d ago, source: 24/7 Wall St

Aclaris Therapeutics Inc. (NASDAQ: ACRS) says it has received an update from the U.S. Food and Drug Administration (FDA) indicating that the agency has allowed an investigational New Drug ...

Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study

24d ago, source: Nasdaq

Aclaris Therapeutics, Inc. ACRS announced that the FDA has allowed an investigational new drug application (IND) to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in ...

Aclaris gains ~8% after filing IND for ATI-1777 in dermatitis

5d ago, source: Seeking Alpha

(NASDAQ:ACRS) has submitted an Investigational New Drug application to the FDA for ATI-1777, a topical "soft" Janus kinase 1/3 inhibitor, for moderate-to-severe atopic dermatitis (AD).“Soft” JAK ...

Dermatological Therapeutics Market- Growth Insight, Trends By Leading Companies, Regional Outlook end of 2027

4d ago, source: MarketWatch

Recent report published by research nester titled "Global Dermatological Therapeutics Market: Global Demand Analysis ...

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

26d ago, source: GlobeNewswire

17 juin 2020 07h01 HE | Source : Aclaris Therapeutics, Inc. FDA Allows IND to Study ATI-450 in Hospitalized Patients with COVID-19 Aclaris Supports Investigator-Initiated Clinical Trial Sponsored ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.